Esteban Garcia-Gallo

Esteban Garcia-Gallo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
EPEkaterina Pazukhina
Ekaterina Pazukhina
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
LRLuis F Reyes
Luis F Reyes
AKAnders Benjamin Kildal
Anders Benjamin Kildal
WJWaasila Jassat
Waasila Jassat
LSLouise Sigfrid
Louise Sigfrid
Introduction A proportion of people develop Long Covid after acute COVID-19, but with most studies concentrated in high-income countries (HICs), the global burden is largely unknown. Our study aims to characterise long-term COVID-19 sequelae in populations globally and compare the prevalence of reported symptoms in HICs and low-income and middle-income countries (LMICs). Methods A prospective, observational study in 17 countries in Africa, Asia, Europe and South America, including adults with confirmed COVID-19 assessed at 2 to <6 and 6 to <12 months post-hospital discharge. A standardised case report form developed by International Severe Acute Respiratory and emerging Infection Consortium’s Global COVID-19 Follow-up working group evaluated the frequency of fever, persistent symptoms, breathlessness (MRC dyspnoea scale), fatigue and impact on daily activities. Results Of 11 860 participants (median age: 52 (IQR: 41–62) years; 52.1% females), 56.5% were from HICs and 43.5% were from LMICs. The proportion identified with Long Covid was significantly higher in HICs vs LMICs at both assessment time points (69.0% vs 45.3%, p<0.001; 69.7% vs 42.4%, p<0.001). Participants in HICs were more likely to report not feeling fully recovered (54.3% vs 18.0%, p<0.001; 56.8% vs 40.1%, p<0.001), fatigue (42.9% vs 27.9%, p<0.001; 41.6% vs 27.9%, p<0.001), new/persistent fever (19.6% vs 2.1%, p<0.001; 20.3% vs 2.0%, p<0.001) and have a higher prevalence of anxiety/depression and impact on usual activities compared with participants in LMICs at 2 to <6 and 6 to <12 months post-COVID-19 hospital discharge, respectively. Conclusion Our data show that Long Covid affects populations globally, manifesting similar symptomatology and impact on functioning in both HIC and LMICs. The prevalence was higher in HICs versus LMICs. Although we identified a lower prevalence, the impact of Long Covid may be greater in LMICs if there is a lack of support systems available in HICs. Further research into the aetiology of Long Covid and the burden in LMICs is critical to implement effective, accessible treatment and support strategies to improve COVID-19 outcomes for all.

8 August 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LRLuis F Reyes
Luis F Reyes
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
JPJennifer Pinedo
Jennifer Pinedo
MSManuela Saenz-Valcarcel
Manuela Saenz-Valcarcel
LCLeo Anthony Celi
Leo Anthony Celi
GWGrant Waterer
Grant Waterer
To the Editor—We have read with great interest the article published by Azevedo do Carmo and colleagues [ 1]. The Pneumonia SHOCK score might be a useful tool for predicting mortality in patients admitted to the intensive care unit (ICU) due to pneumonia (either hospital or community acquired). Importantly, we would like to highlight the fact that the variables included in the study are easily obtained within the first 6 hours of admission, which makes the Pneumonia SHOCK easy to calculate. This new score was shown to be superior to traditional scores such as the Simplified Acute Physiology Score (SAPS) III (SAPS-III), quick-Sepsis Related Organ Failure Assessment (qSOFA), CURB-65, and CRB-65 with respect to prediction of hospital mortality [ 1]. To further assess generalizability and discrimination for prediction of long-term survival (30-day and 1-year mortality), we used the Medical Information Mart for Intensive Care (MIMIC) III database, which includes 53 423 patients admitted to Beth Israel Deaconess Medical Center in Boston, Massachusetts [ 2]. Then, we identified adult patients diagnosed with pneumonia by using the International Classification of Diseases, 9th revision (ICD-9), codes entered in hospital discharge records. A cohort with 3656 patients comprised our analysis. Using the variables collected within the first 24 hours of hospital admission, we calculated the Pneumonia SHOCK score, SAPS-II, CURB-65, qSOFA, Logistic Organ Dysfunction Score (LODS), and Oxford Acute Severity of Illness Score (OASIS) scores. Then, we determined the area under the curve (AUC) for each score to predict ICU/hospital mortality and 30-day and 1-year mortality. We found that the performance of the Pneumonia SHOCK score to predict ICU mortality was promising (AUC, .736; 95% confidence interval [CI], .699–.772). However, when evaluating this score and its prediction of longer-term outcomes, we found that its sensitivity and specificity drop significantly ( Figure 1). Moreover, we found that the frequently used pneumonia score, CURB-65, had an inferior prediction accuracy for all the outcomes assessed (ICU mortality: AUC, .679; 95% CI, .643–.715) ( Figure 1) [ 3]. In contrast, SAPS-II showed an excellent prediction accuracy for ICU/hospital, 30-day, and 1-year mortality. Most importantly, none of the pneumonia-specific scores accurately predicted 30-day and 1-year mortality in our cohort.

30 August 2024 in Epidemiologia
Verified
Journal Article
Open access
PDF file
LMLaura Merson
Laura Merson
SDSara Duque
Sara Duque
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
TYTrokon Omarley Yeabah
Trokon Omarley Yeabah
JRJamie Rylance
Jamie Rylance
IGISARIC Clinical Characterisation Group
ISARIC Clinical Characterisation Group
Standardised forms for capturing clinical data promote consistency in data collection and analysis across research sites, enabling faster, higher-quality evidence generation. ISARIC and the World Health Organization have developed case report forms (CRFs) for the clinical characterisation of several infectious disease outbreaks. To improve the design and quality of future forms, we analysed the inclusion and completion rates of the 243 fields on the ISARIC-WHO COVID-19 CRF. Data from 42 diverse collaborations, covering 1886 hospitals and 950,064 patients, were analysed. A mean of 129.6 fields (53%) were included in the adapted CRFs implemented across the sites. Consistent patterns of field inclusion and completion aligned with globally recognised research priorities in outbreaks of novel infectious diseases. Outcome status was the most highly included (95.2%) and completed (89.8%) field, followed by admission demographics (79.1% and 91.6%), comorbidities (77.9% and 79.0%), signs and symptoms (68.9% and 78.4%), and vitals (70.3% and 69.1%). Mean field completion was higher in severe patients (70.2%) than in all patients (61.6%). The results reveal how clinical characterisation CRFs can be streamlined to reduce data collection time, including the modularisation of CRFs, to offer a choice of data volume collection and the separation of critical care interventions. This data-driven approach to designing CRFs enhances the efficiency of data collection to inform patient care and public health response.

16 March 2026 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
MNMaria Magdalene Namaganda
Maria Magdalene Namaganda
SGStathis Gennatas
Stathis Gennatas
LMLaura Merson
Laura Merson
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
TETom Edinburgh
Tom Edinburgh
Gerald MboowaGerald Mboowa
Gerald Mboowa
The scale-up of antiretroviral therapy (ART) has transformed the HIV epidemic in sub-Saharan Africa, yet longitudinal public health insights from national programmatic cohorts remain scarce. As global targets move toward epidemic control and elimination of virological failure, understanding how profiles and outcomes of people living with HIV (PLWH) evolve in real-world settings is essential. The AIDS Support Organisation (TASO), Uganda’s largest HIV care provider, maintains one of the longest-running national registries of PLWH. We aimed to generate insights to inform targeted interventions, optimize programmatic responses and improve long-term care for PLWH in resource-constrained settings. We conducted a secondary analysis of routinely collected data within an open cohort of 54,348 PLWH enrolled at 11 TASO clinics between 2014–2024. Descriptive statistics summarized demographic, clinical, immunological, behavioral and socioeconomic characteristics at baseline and follow-up. At most recent recorded follow-up, 60.4% of PLWH were female with median age of 39 years (IQR 31–47); 55% aged 25–44 years. At ART initiation, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens dominated (>90% through 2017), by 2024, > 99% of ART initiations were dolutegravir (DTG)- based, aligning with national policy. Immune recovery improved over study period; however, 12% still presented with CD4 < 200 cells/µL. Most PLWH initiated care in WHO stage I–II, and prevalence of advanced disease declined further at last record. Self-reported adherence exceeded 95%. Tuberculosis was the most frequent infectious comorbidity (5% prior history), whereas hypertension (3.9%) and diabetes (2.5%) were the leading non-communicable conditions. Socioeconomic vulnerability reported 57% with irregular income and 21% unemployed. Psychosocial stressors, including poverty and stigma, were common. Findings show progress alongside persistent gaps and structural barriers. They mandate earlier diagnosis, integrated tuberculosis and non-communicable disease management, strengthened socioeconomic support, and risk-stratified care using predictive modeling to reduce virological failure and drive Uganda toward 95–95–95 targets in resource-constrained settings.

30 June 2025
Verified
Journal Article
Open access
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
Global Preparedness for Clinical Research in Emerging Infections: Lessons from ISARIC’s Data-Driven Covid-19 Response Esteban Garcia-Gallo1*, Tom Edinburgh, Sara Duque Vallejo, Dhruv Darji, Barbara Wanjiru Citarella, Luis Felipe Reyes, Elise Pesonel, Laura Merson JASPI June 2025 / Volume 3 /Issue 2 Copyright: © Author(s). This is an open-access article distributed under the terms of the […]

26 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LRLuis F Reyes
Luis F Reyes
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
NSNatalia Sanabria-Herrera
Natalia Sanabria-Herrera
SDSara Duque-Vallejo
Sara Duque-Vallejo
AGAndré Emilio Viñán Garcés
André Emilio Viñán Garcés
IMIgnacio Matín-Loeches
Ignacio Matín-Loeches
BACKGROUNDCommunity-acquired pneumonia (CAP) is the leading cause of infectious mortality around the world, and approximately 10-20% of hospitalized CAP patients develop severe infection (sCAP) requiring ICU admission. While factors associated with long-term mortality have been described, existing severity scores inadequately identify patients at highest risk of death after hospital discharge.METHODSWe developed and internally validated a clinical prediction model for 1-year all-cause mortality following hospital discharge in adults with sCAP using 3,074 patients from the MIMIC-IV database. Predictors were selected from demographic, clinical, physiological, and laboratory data collected within 24 hours of ICU admission. Model performance was assessed using discrimination, calibration, and decision curve analysis and compared with SAPS-II, SOFA, CURB-65, and the Charlson Comorbidity Index (CCI).RESULTSThe model incorporated 16 predictors for 1-year mortality, including ‘Age’, ‘ARDS’, ‘Urine output’, ‘GCS’, ‘Invasive ventilation’, ‘Tracheostomy’, ‘BUN’, ‘Total bilirubin’, ‘Heart rate’, ‘Systolic blood pressure’ and ‘Malignancy’. L-SCAP achieved an AUC of 0.81 (95% CI 0.73-0.88) outperforming SAPS II, CCI, SOFA and CURB-65. Calibration demonstrated good agreement, and decision curve analysis indicated superior clinical utility across relevant thresholds.CONCLUSIONSThis mortality prediction tool accurately stratifies long-term risk in patients with sCAP and provides superior prognostic value compared with existing scoring systems. Its use may support individualized risk assessment, optimize post-ICU follow-up, and guide clinical decision-making in critically ill pneumonia survivors.